KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) EBITDA (2016 - 2025)

Abbott Laboratories (ABT) has disclosed EBITDA for 17 consecutive years, with $2.3 billion as the latest value for Q4 2025.

  • Quarterly EBITDA rose 17.79% to $2.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 billion through Dec 2025, up 17.99% year-over-year, with the annual reading at $8.1 billion for FY2025, 17.99% up from the prior year.
  • EBITDA hit $2.3 billion in Q4 2025 for Abbott Laboratories, up from $2.1 billion in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
  • Historically, EBITDA has averaged $1.9 billion across 5 years, with a median of $1.8 billion in 2023.
  • Biggest five-year swings in EBITDA: soared 178.23% in 2021 and later plummeted 48.18% in 2023.
  • Year by year, EBITDA stood at $2.4 billion in 2021, then tumbled by 45.16% to $1.3 billion in 2022, then soared by 36.5% to $1.8 billion in 2023, then rose by 7.36% to $1.9 billion in 2024, then increased by 17.79% to $2.3 billion in 2025.
  • Business Quant data shows EBITDA for ABT at $2.3 billion in Q4 2025, $2.1 billion in Q3 2025, and $2.1 billion in Q2 2025.